In 2023, 35.6% of patients received androgen-deprivation therapy alone. Real-world data suggest that, although guideline-concordant care is on the rise, many US patients with metastatic hormone ...

Platelet level may indicate response to 177Lu PSMA therapy in radium-223 treated patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu PSMA) appears effective following treatment with radium 223 (223 ...

Kidney stones and gallstones may increase the risk for prostate cancer, which could have implications for disease monitoring and prevention in specific populations. Patients with kidney stones or ...

Risk for death significantly lower for patients with return of serum testosterone to normal range value. (HealthDay News) — Serum testosterone (T) recovery to normal levels is associated with a ...

Risk for death higher for individuals with hospital-based care for alcohol, stimulant, opioids versus cannabis use disorder. (HealthDay News) — Individuals who require hospital-based care for ...

About 44% of respondents said they were willing to participate in a clinical trial. In a survey, less than half of cancer patients and their family members said they were willing to participate in ...

(HealthDay News) — A “Man Van” deployed in disadvantaged communities can help identify men at high risk for prostate cancer, according to a study presented at the American Society of ...

In the United States, patients with renal cell carcinoma are more likely to die from COPD than the general population. Chronic obstructive pulmonary disease (COPD) is a major cause of death among ...

Plasma KIM-1 levels may be a useful, noninvasive biomarker for risk prognostication in metastatic RCC. Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with ...

In-hospital deaths among patients hospitalized with bladder cancer in the United States increased from 2008 to 2021, suggesting more work needs to be done to prevent early death in this patient ...

The clinical efficacy of enfortumab vedotin plus pembrolizumab in real-world patients is compatible with that of the phase 3 EV-302 clinical trial. Treatment with enfortumab vedotin plus ...

Anemia and low performance status predict worse survival and greater risk for treatment failure in low-intermediate risk vs low-risk patients with mRCC treated with first-line ICI-based therapy.